CCI Photonics – Lets save a life in 15 minutes: Rapid detection of antimicrobial resistant infectious diseases

抗生素耐药性（AMR）是一个主要的公共卫生威胁，需要开发新的和创新的方法来早期和快速识别AMR微生物。目前用于鉴定AMR微生物的方法通常耗时，需要长达48小时才能得出结果，并且在分析过程中产生大量实验室废物。此外，AMR微生物的延迟鉴定导致不适当的治疗，从而导致发病率和死亡率的增加以及广谱抗生素的过量处方，这进一步加速了AMR的生长。在该项目中，我们开发了一种用于鉴定AMR微生物及其抗生素敏感性谱的快速方法，该方法可以使用来自患者的直接生物流体样品或培养的微生物。我们的方法涉及使用红外光谱分析使用ML获得的结果，这允许准确，灵敏度和特异性高于97%，并有效地识别AMR微生物。该技术具有高度可扩展性，可以轻松集成到现有的实验室工作流程中，使临床医生能够快速准确地识别AMR微生物，并为患者提供适当的抗生素治疗，我们方法的另一个关键创新是，同样的方法可以直接使用生物流体如唾液或尿液，也可以使用常规实验室培养的细菌，方法.这意味着我们的方法可以用于各种临床环境，无论是在诊断微生物学实验室还是作为近患者测试。此外，样品处理中使用的唯一耗材是载玻片，这将显著减少实验室浪费。总体而言，我们的项目已经证明了一种快速鉴定AMR微生物的方法，该方法可以使用直接的患者样品或培养的微生物，光谱分析并用ML分析以获得结果。我们的方法有可能通过确保在感染性疾病的早期使用适当的抗生素并减少耐药感染的传播来改善患者的预后。我们认为，这种方法代表了对抗抗菌素耐药性的重要一步，并有可能使全球患者受益。

Antimicrobial resistance (AMR) is a major public health threat that requires the development of new and innovative methods for early and rapid identification of AMR microorganisms. Current methods for identifying AMR microorganisms are often time-consuming, taking up to 48 hours to yield a result, and produce large amounts of laboratory waste during their analysis. In addition, delayed identification of AMR microorganisms leads to inappropriate treatment leading to an increase in morbidity and mortality rates and excessive prescription of broad spectrum antibiotics which further accelerates the growth of AMRIn this project, we have developed a rapid method for dentification of AMR microorganisms and their antibiotic sensitivity profiling that can use either a direct biofluid sample from the patient or a cultured microorganism. Our approach involves the use of infrared spectroscopy analysed using ML to obtain results, which allows for accurate, with a sensitivity and specificity above 97%, and efficient identification of AMR microorganisms. This technology is highly scalable and can be easily integrated into existing laboratory workflows, allowing clinicians to quickly and accurately identify AMR microorganisms and provide patients with the appropriate antibiotic treatment, ultimately leading to an increase in patients' quality of life.Another key innovation of our approach is that the same method can use either biofluids such as saliva or urine directly or bacteria cultured using routine laboratory methods. This means that our method can be used in a variety of clinical settings either in a diagnostic microbiology lab or as a near patient test.In addition the only consumable used in sample processing is a glass slide which will significantly reduce laboratory waste.Overall, our project has demonstrated a rapid method for identification of AMR microorganisms that can use a direct patient sample or a cultured microorganism to be processed using spectroscopy and analysed with ML to obtain results. Our approach has the potential to improve patient outcomes, by ensuring that appropriate antibiotics can be used early in the course of infectious disease and reduce the spread of drug-resistant infections. We believe that this approach represents a significant step forward in the fight against antimicrobial resistance and has the potential to benefit patients worldwide.